







CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA PATIENT ID : ANKIF30079180 ACCESSION NO : 0080WC008231 AGE : 31 Years SEX : Female ABHA NO : DRAWN : RECEIVED : 21/03/2023 08:58 REPORTED : 22/03/2023 12:49 REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status Final Results Biological Reference Interval Units	ts
--	----

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	13.0		12.0 - 15.0	g/dL
METHOD : CYANMETHEMOGLOBIN METHOD				
RED BLOOD CELL (RBC) COUNT	4.99	High	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	8.60		4.0 - 10.0	thou/µL
PLATELET COUNT	230		150 - 410	thou/µL
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	39.8		36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV)	79.7	Low	83.0 - 101.0	fL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM				
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	26.0	Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.6		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED PARAMETER	14.1	High	11.6 - 14.0	%
MENTZER INDEX	16.0			
MEAN PLATELET VOLUME (MPV)	10.2		6.8 - 10.9	fL
METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	56		40 - 80	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CE	ELLS IMPEDENCE			
LYMPHOCYTES	32		20 - 40	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CE				
MONOCYTES	5		2.0 - 10.0	%
METHOD : LIGHT ABSORBANCE OF CYTCHEMICAL STAINED CE				04
EOSINOPHILS	6		1.0 - 6.0	%
BASOPHILS	1		0 - 1	%

ABSOLUTE NEUTROPHIL COUNT	4.82		2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.75		1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT	0.43	_	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.52	High	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.09		0.02 - 0.10	thou/µL






DIAGNOSTIC REPORT	ent Ref. No. 8000001395293			SRL
CLIENT CODE: C000138383			Cert. No. MC-2351	iagnostics
CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156	24 S CHA PUN Tel :	SCO, SEC NDIGAR JAB, IND 911159	CTOR 11 D H, 160011	
PATIENT NAME : ANKITA			PATIENT ID : ANKI	F30079180
ACCESSION NO : 0080WC008231 A	GE : 31 Years SEX : Female		ABHA NO :	
DRAWN :	RECEIVED : 21/03/2023 08:58		REPORTED : 22/03/2023 12:4	19
REFERRING DOCTOR : SELF			CLIENT PATIENT ID:	
Test Report Status Final	Results		Biological Reference Interva	al Units
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.8			
METHOD : CALCULATED PARAMETER	, 10			
ERYTHROCYTE SEDIMENTATION RA BLOOD	TE (ESR),WHOLE			
E.S.R	26	High	0 - 20	mm at 1 hr
METHOD : MODIFIED WESTERGREN				
GLUCOSE FASTING, FLUORIDE PLAS	МА			
FBS (FASTING BLOOD SUGAR)	111	High	74 - 106	mg/dL
METHOD : HEXOKINASE				
GLYCOSYLATED HEMOGLOBIN(HBA BLOOD	1C), EDTA WHOLE			
HBA1C	5.3		Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4		< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASM	A.			
PPBS(POST PRANDIAL BLOOD SUGAR)	148	High	Non-Diabetes 70 - 140	mg/dL
METHOD : HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	191		< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PER	ROXIDASE		,	
TRIGLYCERIDES	162	High	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
	11		< 10 Low	ma/dl
HDL CHOLESTEROL	44		< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG				





















CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA		PATIENT ID : ANKIF30079180
ACCESSION NO : 0080WC008231	AGE : 31 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 21/03/2023 08:58	REPORTED : 22/03/2023 12:49
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
Test Report Status Final	Results	Biological Reference Interval Units

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia		
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end		
	organ damage. 3. CKD stage 3B or 4. 4. L	DL >190 mg/dl 5. Extreme of a single risk factor. 6.	
	Coronary Artery Calcium - CAC >300 AU.	7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid	
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of p	2. Family history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Thera	oy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	< OR = 60)		













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA

PATIENT NAME	: ANKITA			PATIENT ID:	ANKIF30079180
ACCESSION NO :	0080WC008231	AGE: 31 Years SEX : F	Female ABHA NO :		
DRAWN :		RECEIVED : 21/03/2023 0	8:58 REPORTED	: 22/03/202	3 12:49
REFERRING DOCT	OR: SELF		CLI	ENT PATIENT ID	:

	Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--	--------------------	--------------	---------	-------------------------------	-------

Extreme Risk Group	<or 30<="" =="" th=""><th><or 60<="" =="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or 60<="" =="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.


References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

,,,				
BILIRUBIN, TOTAL	0.29		UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)				
BILIRUBIN, DIRECT	0.09		0.00 - 0.30	mg/dL
METHOD : DIAZOTIZATION				
BILIRUBIN, INDIRECT	0.20		0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER				
TOTAL PROTEIN	7.7		6.6 - 8.7	g/dL
METHOD : BIURET				
ALBUMIN	4.7		3.97 - 4.94	g/dL
METHOD : BROMOCRESOL GREEN				
GLOBULIN	3.0		2.0 - 4.0	g/dL
			Neonates - Pre Mature:	
			0.29 - 1.04	
METHOD : CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO	1.6		1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	48	High	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	93	High	0 - 31	U/L
METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE				
ALKALINE PHOSPHATASE	152	High	35 - 105	U/L
METHOD : PNPP - AMP BUFFER				
GAMMA GLUTAMYL TRANSFERASE (GGT)	34		5 - 36	U/L
METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE				
LACTATE DEHYDROGENASE	192		135 - 214	U/L
METHOD : LACTATE -PYRUVATE				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	9		6 - 20	mg/dL
METHOD : UREASE - UV				















PATIENT ID:

Biological Reference Interval Units



ANKIF30079180

CLIENT CODE : C000138383

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

<u>Final</u>

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA

ACCESSION NO :	0080WC008231	AGE: 31 Years	SEX : Female	ABHA NO :	
DRAWN :		RECEIVED : 21/03	/2023 08:58	REPORTED :	22/03/2023 12:49
REFERRING DOCT	OR: SELF			CLIENT	PATIENT ID:

Results

Test Report Status

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
In second in a Dahadastian	In an and the Managina have also in	laxative, corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration,renal failure,	saline, hyperparathyroidism, diabetes
mellitus, diabetesinsipidus, hyperaldosteronism, inadequate	Addison's disease, RTA type IV, hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics, NSAIDs,	alkalosis, hyperadrenocorticism.
inconce,orar contraceptives.	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample.	Interferences: Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEg/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
J	levels are normal.	(Normal serum chloride)

PHYSICAL EXAMINATION, URINE

COLOR

APPEARANCE

PALE YELLOW

SLIGHTLY HAZY

CHEMICAL EXAMINATION, URINE					
PH	5.5	4.7 - 7.5			
METHOD : REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATO	R METHOD				
SPECIFIC GRAVITY	1.010	1.003 - 1.035			
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PKA CHANGE OF PA	RETREATED POLY ELECTROLYTES)				
PROTEIN	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PROTEIN-ERROR-O	F-INDICATORS PRINCIPLE)				
GLUCOSE	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETRY(GLUCOSE OXIDAE/PEROXIDASE METHOD)					
KETONES	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETRY (SODIUM NITROPRUSSIDE REACTION)					
BLOOD	NOT DETECTED	NOT DETECTED			
METHOD : REFLECTANCE SPECTROPHOTOMETRY (PEROXIDASE METHOD)					
BILIRUBIN	NOT DETECTED	NOT DETECTED			



















CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA DELHI INDIA 8800465156

<u>Final</u>

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN :	RECEIVED : 21/03/2023 08:58	REPORTED : 22/03/2023 12:49
ACCESSION NO : 0080WC008231	AGE : 31 Years SEX : Female	ABHA NO :
PATIENT NAME : ANKITA		PATIENT ID : ANKIF30079180

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Inflammation or immune illnesses Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment			
of kidney impairment			
of kidney impairment			
Diabetes or kidney disease			
s Diabetic ketoacidosis (DKA), starvation or thirst			
Liver disease such as hepatitis or cirrhosis			
Renal or genital disorders/trauma			
Liver disease			
Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases			
Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions			
Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time			
Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein			
Physical stress, fever, dehydration, acute congestive heart failure, renal diseases			
Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice			
arthritis			
Urinary infectionwhen present in significant numbers & with pus cells.			
Vaginitis, cervicitis or salpingitis			

- ,			
ТЗ	143.0	80.00 - 200.00	ng/dL
METHOD : COMPETITIVE (ECLIA)			
T4	10.50	5.10 - 14.10	µg/dL
METHOD : COMPETITIVE (ECLIA)			
TSH (ULTRASENSITIVE)	2.290	Non Pregnant Women 0.27 - 4.20	µIU/mL

1.27 4.2 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15













CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA		PATIENT ID : ANKIF30079180
ACCESSION NO : 0080WC008231	AGE : 31 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 21/03/2023 08:58	REPORTED : 22/03/2023 12:49
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units

METHOD : SANDWICH (ECLIA)

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PAPANICOLAOU SMEAR

TEST METHOD SPECIMEN TYPE REPORTING SYSTEM SPECIMEN ADEOUACY

CONVENTIONAL GYNEC CYTOLOGY TWO UNSTAINED CERVICAL SMEARS RECEIVED 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY SMEARS ARE SATISFACTORY FOR EVALUATION.







Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

REFERENCE :













CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
DRAWN :	RECEIVED : 21/03/2023 08:58	REPORTED : 22/03/2023 12:49
ACCESSION NO : 0080WC00823	L AGE : 31 Years SEX : Female	ABHA NO :
PATIENT NAME : ANKITA		PATIENT ID : ANKIF30079180

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing' s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within

High fasting glucose levels correlate with home glucose monitoring results (week) mean capitary glucose values), there is wide nuctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

() HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

vellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase driving chronic viral heart its, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues analy in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,



Scan to View Details

Page 12 Of 14 回為紹為回 £_{ig} ∎est Scan to View Report









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
24 SCO, SECTOR 11 D
CHANDIGARH, 160011
PUNJAB, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : ANKITA		PATIENT ID : ANKIF30079180
ACCESSION NO : 0080WC008231	AGE : 31 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 21/03/2023 08:58	REPORTED : 22/03/2023 12:49
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:

Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface

of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

End Of Report Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

braucht

Dr.Pranjali Vasisht LAB HEAD

. an


Dr. Nidhi Garo Lab Consultant

Chandni Garg

DR.CHANDNI GARG CONSULTANT PATHOLOGIST







CONDITIONS OF LABORATORY TESTING & REPORTING				
 It is presumed that the test sample belongs to the patient named or identified in the test requisition form. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event. A requested test might not be performed if: Specimen received is insufficient or inappropriate ii. Specimen quality is unsatisfactory iii. Incorrect specimen type iv. Discrepancy between identification on specimen container label and test requisition form 	 SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification. Test results cannot be used for Medico legal purposes. In case of queries please call customer care (91115 91115) within 48 hours of the report. 			
	SRL Limited Fortis Hospital, Sector 62, Phase VIII,			
	Fortis Hospital, Sector 62, Phase VIII, Mohali 160062			



